GlassScriptPhysician profile
Arthur Schueler
NPI 1114991833
$1,154.18
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $151 · 2021: $70.61 · 2022: $96.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $477.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $132.91 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $86.07 | 2019-2021 | |
| Amgen INC. | $71.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $57.38 | 2019 | |
| Pfizer INC. | $52.02 | 2019 | |
| Abbott Laboratories | $44.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.43 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.27 | 2019 | |
| Abbvie INC. | $16.88 | 2022 | |
| Glaxosmithkline, LLC. | $15.19 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Lilly USA, LLC | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Schueler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.